Repeat: Treatment.com AI Provides an Update on the Status of Exercised Warrants
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) has provided an update on the exercising of warrants issued upon conversion of special warrants on June 21, 2024. Nearly 800,000 warrants have been exercised, raising gross proceeds of approximately half a million dollars. The remaining warrants could potentially bring in over $2 million in additional funds.
CEO Dr. Essam Hamza highlighted that this cash injection will help expedite the company's plans, including the launch of 'AI Patient' and 'AI Doctor in the Pocket' products this fall. Treatment.com AI has also mentioned a strong acquisition pipeline under review, which could accelerate their growth strategy.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) ha fornito un aggiornamento sull'esercizio delle warrant emesse a seguito della conversione di warrant speciali il 21 giugno 2024. Quasi 800.000 warrant sono stati esercitati, raccogliendo proventi lordi di circa mezzo milione di dollari. Le warrant rimanenti potrebbero potenzialmente generare oltre 2 milioni di dollari in fondi aggiuntivi.
Il CEO Dr. Essam Hamza ha sottolineato che questo afflusso di liquidità aiuterà ad accelerare i piani dell'azienda, inclusi il lancio dei prodotti 'AI Patient' e 'AI Doctor in the Pocket' questo autunno. Treatment.com AI ha anche menzionato un forte pipeline di acquisizioni in fase di revisione, che potrebbe accelerare la loro strategia di crescita.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) ha proporcionado una actualización sobre el ejercicio de las opciones emitidas tras la conversión de opciones especiales el 21 de junio de 2024. Casi 800,000 opciones han sido ejercidas, recaudando ingresos brutos de aproximadamente medio millón de dólares. Las opciones restantes podrían potencialmente aportar más de 2 millones de dólares en fondos adicionales.
El CEO Dr. Essam Hamza destacó que esta inyección de capital ayudará a acelerar los planes de la empresa, incluyendo el lanzamiento de los productos 'AI Patient' y 'AI Doctor in the Pocket' este otoño. Treatment.com AI también ha mencionado un fuerte pipeline de adquisiciones en revisión, que podría acelerar su estrategia de crecimiento.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF)는 2024년 6월 21일 특별 보증의 전환으로 발행된 보증 행사에 대한 업데이트를 제공했습니다. 거의 800,000개의 보증이 행사되었습니다, 약 50만 달러의 총 수익이 발생했습니다. 남은 보증은 추가적으로 200만 달러 이상의 자금을 유치할 수 있습니다.
CEO Dr. Essam Hamza는 이 자금 주입이 회사의 계획을 가속화하는 데 도움이 될 것이라고 강조하며, 이번 가을에 'AI Patient' 및 'AI Doctor in the Pocket' 제품을 출시할 예정입니다. Treatment.com AI는 또한 강력한 인수 파이프라인을 검토 중이며, 이는 그들의 성장 전략을 가속화할 수 있습니다.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) a fourni une mise à jour sur l'exercice des bons émis lors de la conversion des bons spéciaux le 21 juin 2024. Presque 800 000 bons ont été exercés, générant des bénéfices bruts d'environ 500 000 dollars. Les bons restants pourraient potentiellement rapporter plus de 2 millions de dollars de fonds supplémentaires.
Le PDG Dr. Essam Hamza a souligné que cette injection de liquidités aidera à accélérer les projets de l'entreprise, y compris le lancement des produits 'AI Patient' et 'AI Doctor in the Pocket' cet automne. Treatment.com AI a également mentionné un fort pipeline d'acquisitions en cours d'examen, ce qui pourrait accélérer leur stratégie de croissance.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) hat ein Update zu der Ausübung der bei der Umwandlung von Sonderwarrants am 21. Juni 2024 ausgegebenen Warrants bereitgestellt. Fast 800.000 Warrants wurden ausgeübt, was Bruttoeinnahmen von etwa einem halben Million Dollar generiert hat. Die verbleibenden Warrants könnten potenziell über 2 Millionen Dollar an zusätzlichen Mitteln einbringen.
CEO Dr. Essam Hamza hob hervor, dass dieser Geldzufluss dabei helfen wird, die Pläne des Unternehmens zu beschleunigen, einschließlich der Markteinführung der Produkte 'AI Patient' und 'AI Doctor in the Pocket' in diesem Herbst. Treatment.com AI hat auch einen starken Akquisitionspipeline erwähnt, die überprüft wird und deren Wachstumstrategie beschleunigen könnte.
- Nearly 800,000 warrants exercised, raising approximately $500,000
- Remaining warrants could potentially bring in over $2 million
- Plans to launch 'AI Patient' and 'AI Doctor in the Pocket' products in fall 2024
- Strong acquisition pipeline under review for potential growth acceleration
- None.
●~800,000 warrants exercised since free trading was announced raising close to half a million dollars.
●Remaining warrants could bring over
●Robust acquisition pipeline
VANCOUVER, British Columbia, July 24, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”), a healthcare tech company transforming patient care with AI-driven clinical insights is pleased to provide the market with an update on the exercising of the warrants which were issued upon conversion of the special warrants on June 21, 2024.
Since the special warrant conversion, the Company is thrilled to announce that almost 800,000 warrants have been exercised raising gross proceeds approximating to half a million dollars.
Dr. Essam Hamza, CEO of Treatment.com AI, comments: “These warrant exercises underscore the strong investor support for our company. The cash injection enables us to expedite our plans at a time when both the investor and healthcare markets are looking for credible AI solutions to mitigate the challenges faced by our healthcare systems. Apart from our previously announced plans to launch our “AI Patient” and “AI Doctor in the Pocket'' products this fall, we also have a strong acquisition pipeline under review that could provide an accelerated timeline for our growth strategy. We look forward to the exercising of the remaining warrants which could bring another
About Treatment.com AI Inc.
Treatment.com AI is a company utilizing AI to positively disrupt the healthcare sector and impact current inefficiencies and challenges. Over the past 7+ years and with the input of hundreds of healthcare professionals globally, Treatment.com AI has built the world’s most intelligent, personalized healthcare AI engine, the Global Library of Medicine (GLM). Providing the highest qualified clinical information and support to all healthcare professionals, the GLM delivers >
FOR ADDITIONAL INFORMATION, CONTACT:
Dr. Essam Hamza, CEO
If you would like to find out more about Treatment’s products and services, please email at info@treatment.com
For media inquiries, contact: media@treatment.com
Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955
Cautionary Statements
This news release contains forward-looking statements that are based on Treatment.com AI’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment.com believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment.com undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
![](https://ml.globenewswire.com/media/MjgzNmVmMTgtZTE1Yi00MzIzLWJlODktMzEyZDQ2ZTgzNzZiLTUwMDEyMTk0OQ==/tiny/Treatment-com-AI-Inc-.png)
FAQ
How many warrants were exercised for Treatment.com AI (TREIF) in July 2024?
What is the potential additional funding from remaining warrants for Treatment.com AI (TREIF)?
What new products is Treatment.com AI (TREIF) planning to launch in fall 2024?